QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors

Advanced Tumor Clinical Trial

Official title:
Phase Ia Clinical Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLF32004 for Injection Monotherapy in Patients With Advanced Malignant Tumors

Status Recruiting

Clinical Trial Summary

To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients with advanced malignancies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05108779
Study type	Interventional
Source	Qilu Pharmaceutical Co., Ltd.
Contact	Jin Li
Phone	021-38804518
Email	sunypclinicaltrial@163.com
Status	Recruiting
Phase	Phase 1
Start date	November 9, 2021
Completion date	December 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05607563` - A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours	Phase 1
Recruiting	`NCT05839106` - Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT02977156` - Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.	Phase 1
Completed	`NCT00502060` - Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer	Phase 1